10,055.0025.9
Stock Analysis, IPO, Mutual Funds, Bonds & More

Lupin enters gynaecology segment

Drug major Lupin on Wednesday said its domestic business will continue to focus on lifestyle segment and it has entered the gynaecology segment this year.

PTI|
Last Updated: Apr 23, 2008, 07.58 PM IST
0Comments
MUMBAI: Drug major Lupin on Wednesday said its domestic business will continue to focus on lifestyle segment and it has entered the gynaecology segment this year.

"We will concentrate on chronic therapeutic areas such as cardiology, neurology, oncology and diabetology. Now we have entered the gynaecology segment," Lupin's India Region Formulations President Sakti Chakraborty said.

The company in the next two years is eyeing five per cent market share in the gynaecology segment. It has formed a separate division called Lupin Femina to manage the gynaecology division.

As a first step, it has launched an oral contraceptive pill for women, Yamini.

"Lupin Femina would concentrate on classical problems such as infertility, invitro fertilisation and iron therapy," he said.

Two years ago, the company has entered the respiratory segment dominated by Cipla. In the last few years, Lupin has been entering chronic therapeutic areas such as cardiology, neurology, oncology and diabetology.

Lupin shares on BSE closed at Rs 551.50, up 1.72 per cent.
(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)
Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service